Internal Medicine · Vineland, NJ
NPI
1275769978
Since 2009
Specialty
Internal Medicine
Code 207R00000X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
1505 W. Sherman Avenue, Suite 101
Vineland, NJ, 08360
Phone (856) 696-9550
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.6M
112,598 services
Medicare patients, 2024
590
Average age 74
Drug cost, 2024
$4.6M
1,556 prescriptions
Company payments, 2025
$2,367
From 44 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Omar Al Ustwani was code J1439 (injection, ferric carboxymaltose, 1 mg), 27,000 times for 25 patients. In total Omar Al Ustwani billed 112,598 services in 105 codes, and Medicare paid $1.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-11-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 27,000 | 25 | $0.88 | $24K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 4,800 | 11 | $44.91 | $216K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 4,349 | 15 | $0.12 | $511 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 3,300 | 15 | $20.46 | $68K |
| J9267 Injection, paclitaxel, 1 mg | Office | 3,261 | 12 | $0.08 | $266 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 3,251 | 20 | $5.52 | $18K |
| J0897 Injection, denosumab, 1 mg | Office | 3,060 | 11 | $20.63 | $63K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,400 | 29 | $6.40 | $15K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,150 | 56 | $0.09 | $104 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 790 | 35 | $0.71 | $564 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 692 | 23 | $0.07 | $50.67 |
| 85025 Blood Count | Office | 678 | 292 | $7.60 | $5,152 |
| 99213 Office E&M - Established | Office | 543 | 326 | $72.83 | $40K |
| 96375 Injection Administration | Office | 317 | 63 | $13.71 | $4,347 |
| 99214 Office E&M - Established | Office | 270 | 139 | $110.65 | $30K |
By year: 2022 $2.3M for 129,834 services; 2023 $1.9M for 131,785 services; 2024 $1.6M for 112,598 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 678 | 292 | $7.60 | $5,152 |
| 80053 Clinical Chemistry | 31 | 21 | $10.35 | $321 |
Medicare prescription drug claims, 2024
In 2024, the drug Omar Al Ustwani prescribed most often to Medicare patients was Eliquis (Apixaban), with 134 prescriptions and refills. In total Omar Al Ustwani wrote 1,556 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 134 | 164 | 34 | $92K |
| Anastrozole Generic | 98 | 191 | 24 | $1,898 |
| Xarelto Rivaroxaban | 61 | 114 | 17 | $62K |
| Procrit Epoetin Alfa | 59 | 60 | 13 | $77K |
| Letrozole Generic | 56 | 134 | 20 | $1,363 |
| Oxycodone Hcl Generic | 53 | 53 | 21 | $1,258 |
| Pantoprazole Sodium Generic | 40 | 44 | 13 | $290 |
| Mirtazapine Generic | 36 | 54 | 15 | $262 |
| Dexamethasone Sodium Phosphate Generic | 33 | 33 | Under 11 | $88.39 |
| Tamoxifen Citrate Generic | 33 | 74 | Under 11 | $851 |
| Prednisone Generic | 29 | 37 | 16 | $134 |
| Keytruda Pembrolizumab | 29 | 33 | Under 11 | $434K |
| Revlimid Lenalidomide | 27 | 27 | Under 11 | $458K |
| Megestrol Acetate Generic | 26 | 26 | 11 | $895 |
| Dexamethasone Generic | 25 | 33 | 13 | $484 |
Brand drugs: 627 claims; generic drugs: 929 claims; opioid claims: 95.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Omar Al Ustwani $2,367 ($2,367 in general payments such as food, travel and fees) from 44 companies. The largest payer was Novartis Pharmaceuticals Corporation with $264.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 14 | $264 |
| GlaxoSmithKline, LLC. GSK | 13 | $213 |
| Daiichi Sankyo Inc. 4568.T | 8 | $160 |
| Pfizer Inc. PFE | 8 | $124 |
| Merck Sharp & Dohme LLC MRK | 6 | $122 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $114 |
| Abbvie Inc. ABBV | 6 | $95.05 |
| Array Biopharma Inc PFE | 5 | $76.47 |
| Astellas Pharma US Inc 4503.T | 4 | $75.65 |
| Celgene Corporation BMY | 4 | $68.25 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.